Tumors of Meningothelial Cells: Meningiomas

  • Serge Weis
  • Michael Sonnberger
  • Andreas Dunzinger
  • Eva Voglmayr
  • Martin Aichholzer
  • Raimund Kleiser
  • Peter Strasser


Meningiomas are usually benign tumors arising from meningeal or arachnoithelial cells. They occur frequently and make up 40–45% of tumors seen in the daily clinical practice. According to biologic behavior, meningioma (with various histologic subtypes) (WHO grade I), atypical meningioma (WHO grade II), and anaplastic meningioma (WHO grade III) are distinguished.

Radiologically, meningiomas present as extra-axial, well-defined mass, attached to the dura with a round, lobulated, or en plaque configuration. Tumor grading on the basis of imaging findings is in the majority of the cases impossible.

Histologically, meningiomas (WHO grade I) are made up of tumor cells with uniform size, oval nuclei, delicate chromatin, and resemblance of arachnoid cap cells. Tumor cells form a syncytium with undiscernible cell processes. Atypical meningiomas (WHO grade II) show increased mitotic activity, brain invasion on histology, or at least increased cellularity, small cells with a high nuclear-to-cytoplasmic ratio, prominent nucleoli, sheeting (i.e., uninterrupted patternless or sheet-like growth), and foci of spontaneous (i.e., not iatrogenically induced) necrosis. Anaplastic (malignant) meningioma (WHO grade III) shows malignant cytology and/or markedly elevated mitotic activity.

Molecular changes affect the hedgehog (Hh) and the Wnt (“wingless”) pathways as well as the RB (retinoblastoma)/TP53 (tumor protein 53), the PI3K (phosphatidylinositol 3-kinase)/Akt, the MAPK (mitogen-activated protein kinase), and the Notch signaling pathways. Chromosomal aberrations and mutations are common. As epigenetic changes DNA methylation shows promoter hypermethylation of several tumor suppressor genes (e.g., TIMP-3, MEG3, NDRG2, and HOXA7, 9 and 10). Distinct expression patterns of genes of the Hh and Wnt pathways were described.

Treatment consists of surgery. Radiation is applied in high-grade tumors. Outcome is usually good.

Selected References

  1. Agrawal V, Ludwig N, Agrawal A, Bulsara KR (2007) Intraosseous intracranial meningioma. AJNR Am J Neuroradiol 28(2):314–315Google Scholar
  2. Al-Faham Z, Kassir MA, Wood D, Balon HR (2016) Appearance of meningioma on 99mTc-HMPAO SPECT: correlation with MRI. J Nucl Med Technol 44(2):90–91. Scholar
  3. Bi WL, Mei Y, Agarwalla PK, Beroukhim R, Dunn IF (2016a) Genomic and epigenomic landscape in meningioma. Neurosurg Clin N Am 27(2):167–179. Scholar
  4. Bi WL, Zhang M, Wu WW, Mei Y, Dunn IF (2016b) Meningioma genomics: diagnostic, prognostic, and therapeutic applications. Front Surg 3:40. Scholar
  5. Choy W, Kim W, Nagasawa D, Stramotas S, Yew A, Gopen Q, Parsa AT, Yang I (2011) The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus 30(5):E6. Scholar
  6. Cimino PJ (2015) Malignant progression to anaplastic meningioma: neuropathology, molecular pathology, and experimental models. Exp Mol Pathol 99(2):354–359. Scholar
  7. Cornelius JF, Langen KJ, Stoffels G, Hanggi D, Sabel M, Jakob Steiger H (2012) Positron emission tomography imaging of meningioma in clinical practice: review of literature and future directions. Neurosurgery 70(4):1033–1041.; discussion 1042Google Scholar
  8. Di Vinci A, Brigati C, Casciano I, Banelli B, Borzi L, Forlani A, Ravetti GL, Allemanni G, Melloni I, Zona G, Spaziante R, Merlo DF, Romani M (2012) HOXA7, 9, and 10 are methylation targets associated with aggressive behavior in meningiomas. Transl Res 160(5):355–362. Epub 2012 Jun 1023Google Scholar
  9. Ellis JA, D'Amico R, Sisti MB, Bruce JN, McKhann GM, Lavine SD, Meyers PM, Strozyk D (2011) Pre-operative intracranial meningioma embolization. Expert Rev Neurother 11(4):545–556. Scholar
  10. Hallinan JT, Hegde AN, Lim WE (2013) Dilemmas and diagnostic difficulties in meningioma. Clin Radiol 68(8):837–844. Scholar
  11. Kishida Y, Natsume A, Kondo Y, Takeuchi I, An B, Okamoto Y, Shinjo K, Saito K, Ando H, Ohka F, Sekido Y, Wakabayashi T (2012) Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis 33(2):436–441. Epub 2011 Nov 1018Google Scholar
  12. Kleihues P, Burger PC, Scheithauer BW (1993) Histological typing of tumours of the central nervous system, 2nd edn. Springer, BerlinGoogle Scholar
  13. Kobayashi K, Okudera H, Tanaka Y (1992) Surgical considerations in skull base meningioma, 1st edn. International Skull Base CongressGoogle Scholar
  14. Laurendeau I, Ferrer M, Garrido D, D’Haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I, Szijan I (2010) Gene expression profiling of the hedgehog signaling pathway in human meningiomas. Mol Med 16(7–8):262–270. Epub 02010 Mar 00026Google Scholar
  15. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ (2000) Meningiomas. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system, 3rd edn. IARC Press, Lyon, pp 176–184Google Scholar
  16. Maclean J, Fersht N, Short S (2014) Controversies in radiotherapy for meningioma. Clin Oncol (R Coll Radiol) 26(1):51–64. Scholar
  17. Paek SH, Kim DG, Park CK, Phi JH, Kim YY, Im SY, Kim JE, Park SH, Jung HW (2006) The role of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in microcystic meningiomas. Oncol Rep 16(1):49–56Google Scholar
  18. Paldor I, Awad M, Sufaro YZ, Kaye AH, Shoshan Y (2016) Review of controversies in management of non-benign meningioma. J Clin Neurosci 31:37–46. Scholar
  19. Perez-Magan E, Rodriguez de Lope A, Ribalta T, Ruano Y, Campos-Martin Y, Perez-Bautista G, Garcia JF, Garcia-Claver A, Fiano C, Hernandez-Moneo JL, Mollejo M, Melendez B (2010) Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro-Oncology 12(12):1278–1290. Epub 2010 Aug 1274Google Scholar
  20. Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A (2007) Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer, Lyon, pp 164–172Google Scholar
  21. Perry A, Louis DN, Budka H, von Deimling A, Sahm F, Mawrin C, Rushing EJ (2016a) Meningioma variants. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, revised 4th edn. IARC, Lyon, pp 237–245Google Scholar
  22. Perry A, Louis DN, Budka H, von Deimling A, Sahm F, Rushing EJ, Mawrin C, Claus EB, Loeffler J, Sadetzki S (2016b) Meningioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, revised 4th edn. IARC, Lyon, pp 232–237Google Scholar
  23. Pham MH, Zada G, Mosich GM, Chen TC, Giannotta SL, Wang K, Mack WJ (2011) Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. Neurosurg Focus 30(5):E7. Scholar
  24. Saloner D, Uzelac A, Hetts S, Martin A, Dillon W (2010) Modern meningioma imaging techniques. J Neuro-Oncol 99(3):333–340. Scholar
  25. Saydam O, Shen Y, Wurdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM, Breakefield XO (2009) Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol 29(21):5923–5940. Epub 02009 Aug 00324Google Scholar
  26. Shi L, Jiang D, Sun G, Wan Y, Zhang S, Zeng Y, Pan T, Wang Z (2012) miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. J Neuro-Oncol 110(2):155–162. Epub 12012 Aug 11014Google Scholar
  27. Shibuya M (2015) Pathology and molecular genetics of meningioma: recent advances. Neurol Med Chir 55(1):14–27. Scholar
  28. Shiroishi MS, Boxerman JL, Pope WB (2016a) Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma. Neuro-Oncology 18(4):467–478. Scholar
  29. Shiroishi MS, Cen SY, Tamrazi B, D’Amore F, Lerner A, King KS, Kim PE, Law M, Hwang DH, Boyko OB, Liu CS (2016b) Predicting meningioma consistency on preoperative neuroimaging studies. Neurosurg Clin N Am 27(2):145–154. Scholar
  30. Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20(1):22–39Google Scholar
  31. Toh CH, Castillo M, Wong AM, Wei KC, Wong HF, Ng SH, Wan YL (2008) Differentiation between classic and atypical meningiomas with use of diffusion tensor imaging. AJNR Am J Neuroradiol 29(9):1630–1635. Scholar
  32. van den Munckhof P, Christiaans I, Kenter SB, Baas F, Hulsebos TJ (2012) Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. Neurogenetics 13(1):1–7. Epub 12011 Oct 10026Google Scholar
  33. Vranic A, Peyre M, Kalamarides M (2012) New insights into meningioma: from genetics to trials. Curr Opin Oncol 24(6):660–665. Scholar
  34. Yao A, Pain M, Balchandani P, Shrivastava RK (2018) Can MRI predict meningioma consistency?: a correlation with tumor pathology and systematic review. Neurosurg Rev 41(3):745–753. Scholar
  35. Yuzawa S, Nishihara H, Tanaka S (2016) Genetic landscape of meningioma. Brain Tumor Pathol 33(4):237–247. Scholar
  36. Zhang H, Rodiger LA, Shen T, Miao J, Oudkerk M (2008) Perfusion MR imaging for differentiation of benign and malignant meningiomas. Neuroradiology 50(6):525–530. Scholar
  37. Zhi F, Zhou G, Wang S, Shi Y, Peng Y, Shao N, Guan W, Qu H, Zhang Y, Wang Q, Yang C, Wang R, Wu S, Xia X, Yang Y (2013) A microRNA expression signature predicts meningioma recurrence. Int J Cancer 132(1):128–136. Epub 22012 Jun 27626Google Scholar
  38. Zülch KJ (1979) Histological typing of tumours of the central nervous system. World Health Organization, GenevaGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  • Serge Weis
    • 1
  • Michael Sonnberger
    • 2
  • Andreas Dunzinger
    • 3
  • Eva Voglmayr
    • 2
  • Martin Aichholzer
    • 4
  • Raimund Kleiser
    • 2
  • Peter Strasser
    • 5
  1. 1.Division of Neuropathology, Neuromed CampusKepler University Hospital, Johannes Kepler UniversityLinzAustria
  2. 2.Department of Neuroradiology, Neuromed CampusKepler University Hospital, Johannes Kepler UniversityLinzAustria
  3. 3.Department of Neuro-Nuclear Medicine, Neuromed CampusKepler University Hospital, Johannes Kepler UniversityLinzAustria
  4. 4.Department of Neurosurgery, Neuromed CampusKepler University Hospital, Johannes Kepler UniversityLinzAustria
  5. 5.PMU University Institute for Medical & Chemical Laboratory DiagnosticsSalzburgAustria

Personalised recommendations